VPT:CC - Ventripoint Signs on AngioConsult/Angiopro as European Distributor
(TheNewswire)
Toronto, Ontario – TheNewswire –April 7, 2022 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce it has signed Angiopro GmbHas Ventripoint’s European Distributor for Ventripoint’s productsand engaged AngioConsult, their affiliated company to tailor themarketing efforts to the different countries in the EU.
Dr. George Adams, CEO, said “AngioConsult andAngiopro are strong andwell-established compan ies that are recognized forits track record for introducing similar products on the Europeanmarket, so it is exciting to have such an experienced partner.”
Mr. Benjamin J. Rieck, CEO of both companies, said:“ At AngioConsult and Angiopro, we have beenpursuing the goal of bringing innovations to the European market andcontinuously improving patient care since the company was founded. Weare very proud to collaborate with Ventripoint as its very promisingtechnology which aligns with our strategy of providing physicians withpatient screening and diagnostic solutions. ”
AngioConsult and Angiopro are both based in Germany.While AngioConsult is a consulting firm that specializes in marketaccess, product management, sales organizationas well as training programs in one company, Angiopro is a classicdistributor company focusing on the distribution of medical devices and software products inthe cardiology, vascular surgery, and radiology/angiology fields. AngioConsult will combine its consulting arm with its distributionpartner, Angiopro, to position Ventripoint in the European market. AngioConsult was selected based on its reputation in thecardiovascular market, alignment with Ventripoint’s current customerbase, and an extensive distribution network with contacts toprofessional decision makers in the cardiovascular field.
About AngioConsult GmbH:
Since more than 12 years AngioConsult, a German basedhealthcare consulting company, pursues the overarching goal ofbringing healthcare innovation to the patient. The AngioConsult teamis specialized in consulting services for the clinical sector andcombines expertise in research, management, sales, marketing,training/ preclinical and field operations. They provide all skillsneeded to drive projects through the entire product lifecycle and tosupport in overcoming all hurdles on the way. For further informationplease visit angioconsult.de and feel free to contact.
About Angiopro GmbH:
Angiopro is a German family-run company and is areliable partner for the distribution of medical devices since morethan 30 years. The Angiopro team consists of specialists in innovativeproducts and technologies in cardiovascular medicine and stands forexclusive sales, intensive advice, and comprehensive services in thefield of vascular medicine. Due to their special medical knowledge,their extensive distribution network with contacts to professionaldecision makers in the cardiovascular field, Angiopro is a strong andefficient sales partner for medical device and healthcare IT solution companies. If you want to learn more aboutAngiopro’s competencies, please visit angiopro.de and feel free tocontact.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
About VMS+ Technology
VMS+ (Ventripoint Medical System Plus) 3.0 marries thehigh-resolution of cardiac MRI (Magnetic Resonance Imaging) and easeof use of ultrasound with the power of Ventripoint’s proprietary KBR(Knowledge-Based Reconstruction) AI technology. KBR enables physiciansto construct a precise 3D model of the heart and calculate volumes andejection fractions for all chambers of the heart with an accuracyequivalent to MRI using standard ultrasound images obtained using anycardiac ultrasound machine such as General Electric, Phillips,Siemens, etc.
For further information, pleasecontact:
Mr. John Grosso
Mr. Cory Bataan
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company. Although the Company believes that the expectationsand assumptions on which such forward-looking statements andinformation are based are reasonable, undue reliance should not beplaced on the forward-looking statements and information because theCompany can give no assurance that they will prove to becorrect.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2022 TheNewswire - All rights reserved.